This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verma, A.
Right arrow Articles by Burns, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verma, A.
Right arrow Articles by Burns, D. L.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2008, p. 1737-1741, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00081-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Role of the N-Terminal Amino Acid of Bacillus anthracis Lethal Factor in Lethal Toxin Cytotoxicity and Its Effect on the Lethal Toxin Neutralization Assay {triangledown}

Anita Verma, Leslie Wagner, Scott Stibitz, Nga Nguyen, Flor Guerengomba, and Drusilla L. Burns*

Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892

Received 3 March 2008/ Returned for modification 22 April 2008/ Accepted 9 September 2008

The cytotoxic activity of lethal factor (LF), a critical reagent used in the cell-based lethal toxin neutralization assay to assess anthrax vaccines, was shown to depend on the identity of its N-terminal amino acid, which plays a role in the targeting of LF to the proteasome for degradation. These results demonstrate that care must be taken to ensure that LF preparations used in standardized cell-based assays are not altered at their N-terminal ends.

* Corresponding author. Mailing address: CBER, FDA HFM-434, Building 29, Room 130, 8800 Rockville Pike, Bethesda, MD 20892. Phone: (301) 402-3553. Fax: (301) 402-2776. E-mail: drusilla.burns{at}fda.hhs.gov

{triangledown} Published ahead of print on 24 September 2008.

Clinical and Vaccine Immunology, November 2008, p. 1737-1741, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00081-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»